Partnerships

Further unlock the value of the ImmTORâ„¢ platform

Our Partnerships

Selecta has entered into strategic transactions with leading biopharmaceutical companies to further unlock the value of the ImmTORTM platform.

Immtor Approach

Agreement

Indications

2020

Immtor Approach

ENABLE RE-DOSING OF LIFE-SAVING GENE THERAPY

Agreement

Research Option and License Agreement (Global)

Indications

Duchenne Muscular Dystrophy and certain Limb-Girdle Muscular Dystrophy subtypes

2020

Immtor Approach

IMPROVING THE EFFICACY OF BIOLOGICS

Agreement

License Agreement (Global, excluding China)

Indications

Chronic refractory gout

2019

Immtor Approach

ENABLE RE-DOSING OF LIFE-SAVING GENE THERAPY

Agreement

License Agreement (Global)

Indications

Pompe disease

2019

Immtor Approach

ENABLE RE-DOSING OF LIFE-SAVING GENE THERAPY

Agreement

50/50 Collaboration Agreement

Indications

Methylmalonic acidemia and other undisclosed indications


Why we partner

While advancing our own programs, the broad applicability of the ImmTORTM platform gives us the unique ability to address immunogenicity across a range of indications and in combination with a variety of therapeutic approaches. As such, we believe that the best way to use our ImmTORTM platform to help the largest number of patients is to develop strategic partnerships, research collaborations and licensing arrangements.

We are open to discussing opportunities both for partners to use our ImmTOR platform for their own therapies as well as for us to bring therapies in house on our own to optimize with ImmTOR.

Partner with us

Connect with us about partnership opportunities

We are open to discussing opportunities both for partners to use our ImmTOR platform for their own therapies as well as for Selecta to bring therapies in house on our own to optimize with ImmTOR.